Latest Updates

  • Virginia Pharmacists Call to Action

    Feb 10, 2020
    Asking Virginia Pharmacists to please email and call your respective State Senators and Delegates and urge them to vote IN FAVOR of companion bills, HB 1506 and SB 1026. These two bills relate to the prescriptive authority of pharmacists under statewide protocols for critical medications including antibiotics, Tamiflu and hormonal contraceptives.
    Full story
  • NCPA Cheers SCOTUS Decision to Rule on States' Authority to Regulate PBMs

    Jan 23, 2020
    NCPA cheered the U.S. Supreme Court's decision to hear an Arkansas case to decide whether ERISA preempts (supersedes) a state law that regulates pharmacy benefit managers — massive corporate middlemen who have operated in a regulatory no-man's land for decades.
    Full story
  • Georgia Lawmakers Seek to Regulate PBMs to Ensure Patient Access to Life Saving Medications

    Jan 22, 2020
    A Joint Special Committee on Access to Quality Health Care and Insurance convened in Atlanta on January 7th to hear testimony from pharmacists, patients and physicians across the state of Georgia on how pharmacy benefit managers (PBMs) present challenging barriers for patients to gain access to needed medications.
    Full story
  • Ohio Medicaid Reimbursement Call to Action

    Dec 20, 2019
    Ohio officials have expressed they are not hearing from pharmacists – have a voice! View our Ohio Medicaid Reimbursement document to access talking points and resources for contacting your Ohio legislators to inform them about the importance of fair Medicaid reimbursement.
    Full story
  • Advocacy Win for Pharmacists & Patients: DIR Fee Reform Included in Bipartisan Senate Finance Drug Pricing Legislation

    Dec 13, 2019
    On December 6th, the Senate Finance Committee released an updated bipartisan version of S. 2543, the Prescription Drug Pricing Reduction Act (PDPRA), and included language to require pharmacy price concessions be included in negotiated price at the point of sale for Medicare Part D beginning in 2022. This language would also prohibit retroactive DIR fees and would allow positive post point-of-sale incentive payments for pharmacies in addition to establishing pharmacy quality metrics in 2022.
    Full story